Lixisenatide vs Survodutide

Lixisenatide (brand names Adlyxin and Soliqua) is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, and it comes as an injectable medication. Survodutide, on the other hand, is an experimental drug that works on both GLP-1 and glucagon receptors, but it has not yet been approved for any use and is still in development.

AI summary of the sources below.